biologics
Biologics Hit Multiple Targets in Asthma and COPD
The future of pulmonary medicine is rapidly evolving, with biologic therapies hitting multiple targets in asthma ...
OCTOBER 26, 2024
Advanced Therapies for IBD Do Not Appear To Raise Thrombotic Risk
In patients with IBD, neither biologics nor small molecule targeted therapies increase the risk for major adverse ...
JANUARY 1, 2024
FDA Approves Subcutaneous Vedolizumab for Moderate to Severe UC
The FDA has approved a subcutaneous version of Entyvio for maintenance therapy in adults with moderate to severe ...
OCTOBER 5, 2023
Racial Disparities Seen in Use of IBD Medical Therapy
Black patients with IBD are less likely to be treated with certain therapies than white IBD patients, according to ...
JANUARY 17, 2023
Pharms, GI Docs Collaborate on IBD Biologics Use
Acollaboration between pharmacists and gastroenterologists to establish a standardized protocol for use of ...
MAY 6, 2022
IBD Patients Report Their Reactions To Biological Therapies
When IBD patients self-report their adverse reactions to biological therapies, they could provide insights that ...
MAY 6, 2021
UDENYCA® (pegfilgrastim-cbqv)
The rising cost of biological products for oncology supportive care creates an ongoing need for increased ...
NOVEMBER 20, 2020
The Need for Biosimilars in Oncology: Challenges in Development
This monograph examines the growing need for biosimilars in the oncology arena and reviews the many complex aspects ...
APRIL 28, 2020
Study Links Psoriasis Therapy to Improved Heart Disease
Treating psoriasis with biologic drugs that target inflammation can reduce the early plaque buildup that leads to ...
FEBRUARY 14, 2019
FDA’s Dr. Gottlieb Chastises Big Pharma for Biosimilar Entry Delays
Of the 11 biosimilars approved by the FDA, only three have reached the U.S. market.
JULY 20, 2018
When to Stop, Start Meds for Rheumatic Patients Undergoing Hip and Knee Replacements
Periprosthetic joint infections are associated with high morbidity and mortality; perioperative management ...
JUNE 30, 2017
FDA Releases Draft Guidance for Labeling Biosimilar Products
The FDA released draft guidance for industry about the labeling of biosimilar products.
APRIL 1, 2016
